Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-ranging study of etokimab (ANB020) in adults with moderate-to-severe atopic dermatitis
2018-000331-27Phase 2Completed
- Sponsor
- AnaptysBio, Inc.
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing Etokimab dose-ranging with Placebo (2 arms). Primary endpoint: Percent change in EASI score from baseline. Started May 2018; status: completed.
02
Drugs
etokimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2018-000331-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-000331-27.